This summary was created by AI, based on 1 opinions in the last 12 months.
ADMA Biologics, with the symbol ADMA-Q, is viewed as a company that has established earnings, distinguishing it from speculative stocks. However, its current valuation appears steep, trading at around 40x earnings, which might deter potential investors. Analysts highlight the lack of a significant catalyst that could drive stock price appreciation in the short term. As such, it is advisable for investors to consider purchasing shares only when the price declines, to secure a more favorable entry point. Overall, while the company has certain positive attributes, its high valuation and absence of immediate triggers are points of concern for investors at this time.
ADMA Biologics is a American stock, trading under the symbol ADMA-Q on the NASDAQ (ADMA). It is usually referred to as NASDAQ:ADMA or ADMA-Q
In the last year, 1 stock analyst published opinions about ADMA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for ADMA Biologics.
ADMA Biologics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for ADMA Biologics.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of ADMA Biologics published on Stockchase.
On 2025-01-29, ADMA Biologics (ADMA-Q) stock closed at a price of $16.38.
It does have earnings and is not that much of a spec stock, but it's rich at 40x and lacks a catalyst. Buy when shares come down.